Hulleman Caspar W J, de Windt Tommy S, Veerman Karin, Goosen Jon H M, Wagenaar Frank-Christiaan B M, van Hellemondt Gijs G
Sint Maartenskliniek, Orthopedic Surgery, 6574 NA Nijmegen, The Netherlands.
Orthopedisch Centrum Oost Nederland, Orthopedic Center, 7555 DL Hengelo, The Netherlands.
J Clin Med. 2023 Jul 31;12(15):5026. doi: 10.3390/jcm12155026.
The purpose of this review is to provide a systematic and comprehensive overview of the available literature on the treatment of an early prosthetic joint infection (PJI) after revision total knee arthroplasty (TKA) and provide treatment guidelines.
This systematic review was performed in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analysis (PRISMA) guidelines. The search was conducted using the electronic databases of PubMed, Trip, Cochrane, Embase, LILACS and SciElo. After the inclusion of the relevant articles, we extracted the data and results to compose a treatment algorithm for early and acute PJI after revision TKA.
After applying the in- and exclusion criteria, seven articles were included in this systematic review focusing on debridement, antibiotics and implant retention (DAIR) for PJI following revision TKA, of which one was prospective and six were retrospective. All studies were qualified as level IV evidence.
The current literature suggests that DAIR is a valid treatment option for early infections after revision TKA with success rates of 50-70%. Repeat DAIR shows success rates of around 50%. Further research should be aimed at predicting successful (repeat/two-stage) DAIRs in larger study populations, antibiotic regimes and the cost effectiveness of a second DAIR after revision TKA.
本综述旨在对全膝关节置换术(TKA)翻修术后早期人工关节感染(PJI)的现有文献进行系统全面的概述,并提供治疗指南。
本系统综述按照系统评价和Meta分析的首选报告项目(PRISMA)指南进行。检索使用了PubMed、Trip、Cochrane、Embase、LILACS和SciElo等电子数据库。纳入相关文章后,我们提取数据和结果,以构建TKA翻修术后早期和急性PJI的治疗算法。
应用纳入和排除标准后,本系统综述纳入了7篇关注TKA翻修术后PJI清创、抗生素和植入物保留(DAIR)的文章,其中1篇为前瞻性研究,6篇为回顾性研究。所有研究均被判定为IV级证据。
当前文献表明,DAIR是TKA翻修术后早期感染的一种有效治疗选择,成功率为50%-70%。重复DAIR的成功率约为50%。进一步的研究应致力于在更大的研究人群中预测成功的(重复/两阶段)DAIR、抗生素方案以及TKA翻修术后第二次DAIR的成本效益。